Evidence map›Paper›PMID 21471201›Full record

ArticleThe Journal of biological chemistry2011

Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of sirtuin 1.

Jung Ho Back, Hamid Reza Rezvani, Yucui Zhu, Véronique Guyonnet-Duperat, Mohammad Athar, Desiree Ratner, Arianna L Kim

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jung Ho BackDepartment of Dermatology, Columbia University Medical Center, New York, New York 10032, USA.
Hamid Reza Rezvani
Yucui Zhu
Véronique Guyonnet-Duperat
Mohammad Athar
Desiree Ratner
Arianna L Kim
Inserm · FRColumbia University Irving Medical Center · USUniversité de Bordeaux · FRUniversity of Alabama · US

Funding

Role of p53 and ptc tumor suppressive pathways in BCCs development and preventionR01ES015323 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2006 to 2010
$1.7M
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin CancerR01CA138998 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2011 to 2015
$1.5M
Cell cycle regulatory proteins in UVB-skin carcinogenesK01AR048582 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KIM, ARIANNA L · 2003 to 2007
$618k
Chk2 as a target for regulating senescence in skin neoplasiaR03CA125855 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KIM, ARIANNA L · 2007 to 2008
$161k
NCI NIH HHS R01 CA138998NCI NIH HHS R03 CA125855NIAMS NIH HHS K01 AR048582NIAMS NIH HHS K01-AR048582NIEHS NIH HHS R01 ES015323
6 · The paper itself

Abstract

DNA-damaging agents can induce premature senescence in cancer cells, which contributes to the static effects of cancer. However, senescent cancer cells may re-enter the cell cycle and lead to tumor relapse. Understanding the mechanisms that control the viability of senescent cells may be helpful in eliminating these cells before they can regrow. Treating human squamous cell carcinoma (SCC) cells with the anti-cancer compounds, resveratrol and doxorubicin, triggered p53-independent premature senescence by invoking oxidative stress-mediated DNA damage. This process involved the mTOR-dependent phosphorylation of SIRT1 at serine 47, resulting in the inhibition of the deacetylase activity of SIRT1. SIRT1 phosphorylation caused concomitant increases in p65/RelA NF-κB acetylation and the expression of an anti-apoptotic Bfl-1/A1. SIRT1 physically interacts with the mTOR-Raptor complex, and a single amino acid substitution in the TOS (TOR signaling) motif in the SIRT1 prevented Ser-47 phosphorylation and Bfl-1/A1 induction. The pharmacologic and genetic inhibition of mTOR, unphosphorylatable S47A, or F474A TOS mutants restored SIRT1 deacetylase activity, blocked Bfl-1/A1 induction, and sensitized prematurely senescent SCC cells for apoptosis. We further show that the treatment of UVB-induced SCCs with doxorubicin transiently stabilized tumor growth but was followed by tumor regrowth upon drug removal in p53(+/-)/SKH-1 mice. The subsequent treatment of stabilized SCCs with rapamycin decreased tumor size and induced caspase-3 activation. These results demonstrate that the inhibition of SIRT1 by mTOR fosters survival of DNA damage-induced prematurely senescent SCC cells via Bfl-1/A1 in the absence of functional p53.

Indexed as

Cellular SenescenceDNA DamageAcetylationAdaptor Proteins, Signal TransducingAmino Acid SubstitutionAnimalsAntibiotics, AntineoplasticApoptosisCarcinoma, Squamous CellCarrier ProteinsCaspase 3Cell Line, TumorCell SurvivalDoxorubicinEnzyme ActivationHumansAdaptor Proteins, Signal TransducingAntibiotics, AntineoplasticBCL2-related protein A1Carrier ProteinsCASP3 protein, humanCasp3 protein, mouseCaspase 3DoxorubicinMinor Histocompatibility AntigensMTOR protein, humanmTOR protein, mouseProto-Oncogene Proteins c-bcl-2Regulatory-Associated Protein of mTORRELA protein, humanRela protein, mouseRPTOR protein, humanRptor protein, mouseSIRT1 protein, humanSirt1 protein, mouseSirtuin 1TOR Serine-Threonine KinasesTP53 protein, humanTranscription Factor RelATumor Suppressor Protein p53

Identifiers

PMID21471201
PMCPMC3099723
OpenAlexW1985504923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.